Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.
Immunic (IMUX) announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, demonstrated a ...
18h
Hosted on MSNAscletis announces positive results in Phase Ib oral GLP-1RA trialThe Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.
Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...
When I tell people I direct clinical research studies, I often encounter surprise. “Aren’t you a physician?” they ask. It ...
Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...
ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...
Dr. Corey L. Hartman tells ESSENCE how this prescription can have long-term effects not just the body—but also on our skin.
ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control and adding savory flavors are ways that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results